Looks back at patients with kidney cancer treated with pembrolizumab and axitinib
Collects past experiences of adults with metastatic kidney cancer treated with pembrolizumab plus axitinib.
Plain-language title generated from the registry record
Registry title: International Multicentric Study ARON-1
Key facts
- Where
- Province of Macerata, ItalySee the site
Where in Italy
- Ospedale di Macerata, UOC OncologiaProvince of Macerata, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital of Macerata
- Trial code
- NCT05287464
- Record updated
- 26 November 2025
- Original description
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.Read full original descriptionShow less
International Multicentric Study ARON-1
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
Inclusion: Patients aged >18y; Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC; Histologically or radiologically confirmed diagnosis of metastatic disease; First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab.
Exclusion: Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section; Patients without histologically or radiologically confirmed metastatic disease; Patients without histologically confirmed diagnosis of RCC.